RSS | Login | Register

Cefadroxil

Compare to Similar Drugs | Add to Clipboard | View Clipboard | Print | Email

Close [X]

Compare Cefadroxil to:

Generic Name for Cefadroxil

Cefadroxil 500mg; caps.

Legal Classification:

Pharmacological Class for Cefadroxil

Cephalosporin.

Manufacturer of Cefadroxil

Various generic manufacturers

Indications for Cefadroxil

Susceptible urinary tract, skin and skin structure infections, pharyngitis/tonsillitis, impetigo.

Adult dose for Cefadroxil

Uncomplicated UTI: 1–2g once daily or in 2 divided doses. Complicated UTI: 2g/day in 2 divided doses. Skin and skin structure infections: 1g once daily or in 2 divided doses. Pharyngitis/tonsillitis: 1g once daily or in 2 divided doses for 10 days. Renal dysfunction (CrCl <50mL/min): 1g loading dose, then 500mg at increased dosing intervals (see literature). Continue for 3 days after symptoms improve.

Children's dosing for Cefadroxil

UTI, skin and skin structure infections: 30mg/kg/day in 2 divided doses every 12 hours. Pharyngitis/tonsillitis, impetigo: 30mg/kg once daily or in 2 divided doses for 10 days. Renal dysfunction: reduce dose (see literature). Continue for 3 days after symptoms improve.

Also:

Cefadroxil Suspension

Cefadroxil Tablets

Warnings/Precautions for Cefadroxil

Penicillin or other allergy. Discontinue if colitis occurs and treat. Impaired renal function (CrCl <50mL/min). GI disease (esp. colitis). Pregnancy (Cat.B). Nursing mothers.

Interactions for Cefadroxil

Potentiated by probenecid. May cause false (+) Clinitest or Coomb's test.

Adverse Reactions for Cefadroxil

GI upset, anaphylaxis, rash; blood dyscrasias (rare).

How is Cefadroxil supplied?

Contact supplier.

Related Disease:

Infections, bacterial~systemic antiinfectives

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.